![]() |
|
|
Vol. 282, Issue 1, 440-444, 1997
Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health (D.S.M.), Research Triangle Park, North Carolina, Institut fur Pharmazeutische Technologie und Biopharmazie (G.F.), INF 366, D-69120 Heidelberg, Germany, University of Basel/Kantonsspital (J.D.), CH-4031 Basel, Switzerland, and Mount Desert Island Biological Laboratory (D.S.M., G.F., J.D.), Salsbury Cove, Maine
| |
Abstract |
|---|
|
|
|---|
The transport of a fluorescent rapamycin derivative was measured in killifish (Fundulus heteroclitus) renal proximal tubules by means of confocal microscopy and image analysis. Renal cells and tubular lumens rapidly accumulated the rapamycin analog from the medium and attained steady state within 60 min. At steady state, luminal fluorescence intensity was two to four times higher than cellular fluorescence. Cellular fluorescence intensity was a linear function of medium substrate concentration and was not affected by any treatment used. In contrast, luminal fluorescence exhibited a saturable component as the medium concentration of the rapamycin derivative was increased. Secretion into the lumen was blocked by KCN, rapamycin, cyclosporin A and substrates for p-glycoprotein (verapamil, PSC-833 and FK506), but not by substrates for the renal organic anion or organic cation transport systems, such as p-aminohippurate, leukotriene C4 or tetraethylammonium. Finally, rapamycin blocked p-glycoprotein-mediated secretion of a fluorescent cyclosporin A derivative. The data are consistent with the fluorescent rapamycin analog entering proximal tubule cells by simple diffusion and then being pumped into the tubular lumen by p-glycoprotein. They suggest that the parent compound, rapamycin, would be handled similarly.
| |
Introduction |
|---|
|
|
|---|
Rapamycin, is a potent,
macrocyclic immunosuppressive that blocks transduction of cytokine
signals needed for proliferation and maturation of T cells (Sehgal and
Bansbach., 1993; Sehgal et al., 1994
; Kahan et
al., 1995
; Dumont and Su, 1996
). The therapeutic potency of the
drug is up to 100 times greater than that of CSA with a relatively long
half-life in animals and humans (Yatscoff et al., 1992
;
Yatscoff, 1996
). In addition, there is evidence that the renal side
effects of rapamycin, such as tubular atrophy and interstitial
fibrosis, are less severe than for CSA (Thliveris et al.,
1995
). At present, it is not clear whether specific drug transport
systems handle rapamycin or whether it distributes through the body by
simple diffusion. Available data suggest that rapamycin may be capable
of functioning as a MDR-reversing agent by interacting with
p-glycoprotein, thereby increasing the cytotoxicity of
chemotherapeutic agents in multidrug-resistant cells (Arceci et
al., 1992
). The increase in cytotoxic drug accumulation was
observed at concentrations of rapamycin that were similar to those
shown to be effective for other MDR reversal agents, such as CSA and
verapamil.
These findings document an interaction between rapamycin and
p-glycoprotein, but they do not address the question of
whether the drug is a substrate for transport. In the present study we used confocal microscopy and digital image analysis to study the transport of a fluorescent rapamycin derivative, NBD-rapamycin (fig.
1), in intact renal proximal tubules from a teleost
fish. Renal tissue from teleost fish offers several important
advantages for the study of secretory transport mechanisms (Pritchard
and Miller, 1991
). Teleost kidneys contain a high proportion of
proximal tubules that are easily isolated and remain viable for long
periods. When tubules are isolated, broken ends rapidly reseal to form a closed, fluid-filled luminal compartment that only communicates with
the medium through the tubular epithelium. Thus, this tissue has the
appropriate geometry for the study of secretion in intact tubules. When
teleost tubules are used along with fluorescent substrates and
quantitative fluorescence microscopy, the mechanisms driving both
uptake by the cells and secretion into the tubular lumen can be
investigated (Miller and Pritchard, 1991
; Miller, 1995
; Schramm
et al., 1995
). Finally, secretory transport mechanisms found
in teleost tubules appear to be identical with those found in mammalian
proximal tubule (Pritchard and Miller, 1991
, 1993
) and among these is a
potent p-glycoprotein-mediated drug transport pathway
(Miller, 1995
; Schramm et al., 1995
).
|
The results of the present study show that NBD-rapamycin entered killifish proximal tubule cells by simple diffusion and was pumped from cell to tubular lumen by p-glycoprotein.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Rapamycin was obtained from Sigma (St. Louis,
MO). The fluorescent rapamycin derivative was synthesized by coupling
the fluorescent residue 7-bromo-4-nitrobenzofurazan (Merck, Darmstadt,
Germany) to rapamycin. NBD-rapamycin was purified from the reaction
mixture by high-performance liquid chromatography. NBDL-CSA was
synthesized as described previously (Schramm et al., 1995
).
All other chemicals were obtained from commercial sources at the
highest purity available.
Animals and tissue preparation. Killifish (Fundulus heteroclitus) were collected by local fishermen in the vicinity of Mount Desert Island, Maine and maintained in tanks with natural, flowing sea water at the Mount Desert Island Biological Laboratory. For some experiments, killifish were collected near Duke University Marine Laboratory (Beaufort, NC) and maintained in tanks with recirculating, artificial sea water at the National Institute of Environmental Health Sciences.
Renal tubular masses were isolated in a marine teleost saline based on that of Forster and Taggart (1950)Confocal fluorescence microscopy. Tubules in the chamber were mounted on the stage of a confocal microscope. Two systems were used for the present studies. Most of the images were collected with a Noran Confocal Microscope with a Nikon 40× Fluor oil immersion objective (NA, 1.4). Illumination was provided by an Ar laser at 488 nm. A 510-nm dichroic filter and a 515-nm long-pass emission filter were used. Some images were collected by a Zeiss model 410 Inverted Laser Scanning Confocal Microscope with a Zeiss 40× plan-neofluar water immersion objective (NA, 1.3). The microscope was fitted with an Ar-Kr laser also providing light at 488 nm. A 510-nm dichroic filter and a 515-nm long-pass emission filter were used. Neutral density filters and reduced laser power were used to minimize photobleaching. Preliminary experiments showed that under these conditions fluorescence intensities in cells and tubular lumens were reduced by less than 5% from one collected image to the next (below). With these settings, and with photomultiplier gain adjusted so that the average pixel intensity in the lumens of control tubules was 50-150, tissue autofluorescence was undetectable.
To obtain an image, dye-loaded tubules in the chamber were viewed under reduced, transmitted light illumination, and a single proximal tubule with well-defined lumen and undamaged epithelium was selected. The plane of focus was adjusted to cut through the center of the tubular lumen. Then, in confocal fluorescence mode, 128 video frames were averaged (Noran) or a single 8-sec scan of the tubule was collected (Zeiss). The confocal image (512 × 512 × 8 bits) was viewed on a high-resolution monitor and saved to an optical disk. Fluorescence intensities were measured from stored images by an Apple Power Macintosh 7100 computer and NIH Image version 1.58 software as described previously (Miller, 1995Statistics. Data are given as means ± S.E. Means were considered to be statistically different, when the probability value (P) was less than .05 by use of the appropriate paired or unpaired t test.
| |
Results |
|---|
|
|
|---|
In the present experiments, killifish renal proximal tubules were incubated in medium containing a fluorescent rapamycin derivative, confocal fluorescence images were collected and fluorescence distribution patterns analyzed to obtain an indication of dye distribution in the tissue. Data are presented as steady-state fluorescence intensity measurements made over the cellular and luminal regions of the tubules. Two caveats must be kept in mind when interpreting such measurements. First, the signal from a fluorescent probe is sensitive to environment, e.g., pH or solvent polarity. As a result, absolute calibration of dye concentration in a single region of a tissue or a cell is difficult and the constant relating probe fluorescence to concentration could vary from region to region. Second, the steady-state solute concentration in a tissue compartment is a function of all processes governing entry into and exit from that compartment. Changes in steady-state solute concentration indicate that one or more of those processes has been altered. Often, additional knowledge about the nature of the treatment causing the change in concentration can be used to eliminate possibilities.
When killifish renal proximal tubules were incubated in media with
micromolar concentrations of NBD-rapamycin, the fluorescent compound
was seen to accumulate in the tissue. Figure 2 shows a
typical confocal image of a tubule after 60 min incubation in medium
with 1 µM NBD-rapamycin. The image shows that the tubular epithelium
clearly accumulated the compound, but that significantly higher levels
were present in the lumen. The fluorescence intensity in the incubation
medium was substantially lower than that of the tissue. This is the
same overall pattern of fluorescence seen in micrographs of killifish
tubules exposed to dyes handled by specific renal excretory transport
systems present in this tissue and indicates secretion into the urinary
space (Schramm et al., 1995
; Miller, 1995
).
|
Figure 3 shows the time course of accumulation of
fluorescence in the cells and lumens of killifish proximal tubules
incubated in medium with 1 µM NBD-rapamycin. In both tissue
compartments, fluorescence increased rapidly over the first 30 min and
then reached a plateau after about 60 min. At all but the earliest time
point, luminal fluorescence significantly exceeded cellular fluorescence; at steady state (60-90 min) the lumen-to-cell
fluorescence ratio averaged 2.3. In experiments with 94 control tubules
from eight fish this ratio averaged 3.3 (range, 1.8-4.1), which
indicated some fish-to-fish variability. Figure 3 also shows that
addition of 1 mM KCN to the medium had no effect on cellular
fluorescence, but significantly reduced luminal fluorescence. In
KCN-exposed tubules the lumen-to-cell fluorescence ratio was slightly
less than unity. These data from confocal images indicate that
NBD-rapamycin accumulates in the cells and lumens of proximal tubules,
but that only luminal accumulation is dependent on cellular metabolism.
|
The steady-state accumulation and distribution of NBD-rapamycin was
concentration dependent (fig. 4). Cellular fluorescence intensity increased linearly with increasing medium NBD-rapamycin concentration, but luminal fluorescence intensity appeared to saturate
with higher concentrations. As a result, the lumen-to-cell fluorescence
ratio decreased from 4 at 1 µM NBD-rapamycin to 1.8 at 10 µM
NBD-rapamycin.
|
Table 1 shows the effects of various agents on the
transport of 0.5 to 1.0 µM NBD-rapamycin by killifish tubules. None
of the compounds tested altered cellular fluorescence, even though several greatly reduced luminal fluorescence. The parent compound, rapamycin, was a potent inhibitor of luminal accumulation of
NBD-rapamycin, with 1 µM rapamycin reducing luminal fluorescence by
more than 60% and 5 µM reducing luminal fluorescence by more than
80%. Other inhibitors of luminal accumulation included CSA, PSC-833,
FK506 and verapamil (table 1). Some of these (PSC-833 and FK506) were effective at submicromolar concentrations. All of these drugs are
substrates for or modifiers of p-glycoprotein. In contrast, inhibitors of the other xenobiotic transport systems present in killifish proximal tubule, PAH for the classical organic anion system
(Miller and Pritchard, 1991
), TEA for the organic cation system
(Miller, 1995
) and LTC4 for the Na-independent system for large organic anions (Masereeuw et al., 1996
), used at
concentrations that should have blocked transport on those systems,
were without effect (table 1).
|
Finally, we tested the effects of the parent compound, rapamycin, on
the transport of a known substrate for p-glycoprotein, NBDL-CSA, a fluorescent derivative of the immunosuppressive drug, CSA
(Schramm et al., 1995
). Figure 5 shows that
rapamycin, at 1 and 5 µM, reduced luminal fluorescence in a
concentration-dependent manner; rapamycin had no effect on cellular
fluorescence. These data, together with the results showing that both
rapamycin and CSA block secretion of NBD-rapamycin, are consistent with
CSA and rapamycin and their NBD derivatives being handled by a common luminal transporter, p-glycoprotein.
|
| |
Discussion |
|---|
|
|
|---|
Specific membrane transport proteins, e.g., MDR transporters and MDR-associated proteins, are drug-transporting ATPases found in tumor cells, normal cells and also in excretory epithelia (kidney and liver). By mediating active drug efflux from cells and from the body they play a major role in determining drug concentrations reaching sensitive sites on cell surfaces and within cells. Along with drug-metabolizing enzymes, these transporters can be important determinants of drug effectiveness on the one hand and drug toxicity on the other hand. Moreover, because of their wide specificity limits, these transporters also provide a mechanism, competition for transport, by which drugs with very different structures may interact. Thus, it is important to understand not only interactions with enzymes that may metabolize the drugs and modify their actions, but also interactions with specific drug transporters that determine distribution and excretion patterns.
The present experiments demonstrate that a fluorescent analog of
rapamycin, NBD-rapamycin, is taken up by killifish renal proximal
tubules and is transported into the tubular lumen by a concentrative
process. As with other secreted organic solutes, NBD-rapamycin
transport from bath to urinary space was a two-step process, which
consists of uptake at the basolateral membrane of the tubular
epithelial cells followed by efflux from cell to lumen. However, very
different mechanisms were responsible for the two steps in
NBD-rapamycin secretion. Uptake of NBD-rapamycin through the
basolateral plasma membrane was not affected by unlabeled rapamycin or
by other inhibitors of membrane transport or cellular metabolism.
Cellular uptake was a linear function of medium concentration of the
fluorescent derivative. Thus, it is likely that NBD-rapamycin crossed
the basolateral membrane of these renal cells by simple diffusion. In
killifish tubules, a similar diffussive uptake step has been
demonstrated in the secretory transport of two other p-glycoprotein substrates, a fluorescent derivative of CSA
and daunomycin (Schramm et al., 1995
; Miller, 1995
). As with
the fluorescent CSA derivative, the apparent accumulation of
NBD-rapamycin within renal cells (present study) could be explained by
invoking passive mechanisms, such as partitioning into lipid-rich
intracellular compartments and binding to proteins (immunophillins).
In contrast to uptake across the basolateral membrane, transport across
the luminal membrane had all the hallmarks of an active, carrier-mediated process. First, the level of NBD-rapamycin-derived fluorescence measured in the luminal compartment exceeded that in the
cell. Because the luminal space is a simple aqueous compartment, it is
unlikely that this increase in fluorescence is caused by compartmentation, e.g., binding to macromolecules or
partitioning into lipid-rich regions. Second, NBD-rapamycin secretion
was blocked when metabolism was inhibited by KCN. Third, transport from
cell to lumen appeared to saturate as the medium NBD-rapamycin
concentration was increased. Finally, NBD-rapamycin transport from cell
to lumen was inhibited by micromolar concentrations of unlabeled
rapamycin, CSA, PSC-833, FK506 and verapamil. This inhibition was not a
result of disruption of cellular energy metabolism. Incubating
killifish tubules for 60 min with 5 µM CSA, 50 to 100 µM verapamil
or 5 µM rapamycin did not affect the active secretion of fluorescein via the organic anion system (Schramm et al.,
1995
; Miller, 1995
, unpublished data). If these compounds had affected
cell metabolism we would have expected to see inhibition of fluorescein
transport, because the organic anion system is particularly sensitive
to agents that disrupt metabolism or reduce the transmembrane Na gradient (Pritchard and Miller, 1993
). Thus, it appears that
NBD-rapamycin shares a specific, luminal transport system with several
other compounds, and among these is unlabeled rapamycin.
Renal proximal tubule has been shown to possess four distinct transport
pathways for organic xenobiotics (Pritchard and Miller, 1993
; Masereeuw
et al., 1996
; Schramm et al., 1995
; Miller,
1995
): 1) the classical organic anion system (model substrate, PAH); 2)
the organic cation system (model substrate, TEA); 3) a Na-independent system for large organic anions (best inhibitor, LTC4); and
4) p-glycoprotein. Based on the lack of effect of PAH, TEA
and LTC4 on the transport of NBD-rapamycin (table 1), it is
unlikely that the first three pathways are involved in the transport
from cell to lumen of this fluorescent derivative. Rather, all
compounds that were effective inhibitors of NBD-rapamycin secretion
were also substrates for or modifiers of p-glycoprotein.
Consistent with NBD-rapamycin and unlabeled rapamycin being handled by
p-glycoprotein in killifish tubules, rapamycin was a potent
inhibitor of the secretion of NBDL-CSA, a substrate that is transported
only by p-glycoprotein (Schramm et al., 1995
).
The present study is the first to investigate mechanisms of rapamycin transport in any cell type. Assuming that rapamycin and its NBD derivative are handled similarly, the data suggest that in renal proximal tubule both compounds are substrates for transport by p-glycoprotein. Note that this drug-transporting ATPase is expressed in both tumors and normal tissues. As a result, one would expect rapamycin to compete for transport with the large number of drugs and endogenous compounds handled by that transporter. Such interactions at the transporter level could alter drug levels in target cells and in plasma and could also shift urine and bile drug excretion patterns.
| |
Footnotes |
|---|
Accepted for publication March 5, 1997.
Received for publication November 22, 1996.
1 Supported in part by a grant from the Deutsche Forschungsgemeinschaft to G.F. and a travel grant from Mundipharma Pharmaceuticals to J.D.
This study was also supported by a NATO CRG grant.
Send reprint requests to: Dr. David S. Miller, LPC, NIH/NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709.
| |
Abbreviations |
|---|
CSA, cyclosporin A;
DMSO, dimethylsulfoxide;
LTC4, leukotriene C4;
MDR, multidrug
resistance;
NA, numerical aperature;
NBD-rapamycin, (4-nitrobenzofurazan-7-yl)-rapamycin;
NBDL-CSA, [N-
(4-nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporin;
PAH, p-aminohippurate;
TEA, tetraethylammonium.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction? Ann. Pharmacother., July 1, 2008; 42(7): 1037 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu, J. E. Thompson, and M. Carroll mTOR regulates cell survival after etoposide treatment in primary AML cells Blood, December 15, 2005; 106(13): 4261 - 4268. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Marti and F. J. Frey Nephrotoxicity of rapamycin: an emerging problem in clinical medicine Nephrol. Dial. Transplant., January 1, 2005; 20(1): 13 - 15. [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Smith, L. E. Wrenshall, R. F. Nicosia, R. Pichler, C. L. Marsh, C. E. Alpers, N. Polissar, and C. L. Davis Delayed Graft Function and Cast Nephropathy Associated with Tacrolimus Plus Rapamycin Use J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1037 - 1045. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Masereeuw, S. A. Terlouw, R. A. M. H. van Aubel, F. G. M. Russel, and D. S. Miller Endothelin B Receptor-Mediated Regulation of ATP-Driven Drug Secretion in Renal Proximal Tubule Mol. Pharmacol., January 1, 2000; 57(1): 59 - 67. [Abstract] [Full Text] |
||||
![]() |
I. Jakob, I. A. Hauser, F. Thevenod, and B. Lindemann MDR1 in taste buds of rat vallate papilla: functional, immunohistochemical, and biochemical evidence Am J Physiol Cell Physiol, January 1, 1998; 274(1): C182 - C191. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||